BioSpace News Archive

InfuSystem Holdings, Inc. (NYSE American: INFU), (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the third quarter ended September 30, 2022.

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) today announced that Kimberly Blackwell, MD, Chief Executive Officer of Zentalis, will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022 at 1:15 p.m. ET.

Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced its financial results for the third quarter ended September 30, 2022, and recent business highlights.

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced it will report its financial results from the third quarter ended September 30, 2022, before the financial markets open on Monday, November 14, 2022.

Eliem Therapeutics, Inc. announced that members of its senior management team are scheduled to participate in two upcoming investor conferences.

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that management will participate in the Guggenheim 4th Annual Neuro/Immunology Conference on Tuesday, November 15, 2022.

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Instil Bio, Inc. (“Instil”) (NASDAQ: TIL) today announced poster presentations of pre-clinical data and trial-in-progress for the ongoing ITIL-306 Phase 1 clinical trial using the CoStimulatory Antigen Receptor (CoStAR) platform at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), to be held from November 8-12, 2022.

Mereo BioPharma Group plc today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 12:55pm GMT / 07:55am ET.

Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel , Executive Vice President and Chief Financial Officer, will present at the Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022 , at 2:25 p.m. EST.